<DOC>
	<DOCNO>NCT01357590</DOCNO>
	<brief_summary>ThoraflexTM design treatment aneurysm penetrate ulcer descend thoracic aorta . Each system advance transfemoral transiliac approach 0.035 '' guidewire position fluoroscopic control . If necessary , arterial conduit technique may require allow access arterial system . The soft taper tip allows atraumatic insertion vessel , catheter sheath design provide excellent flexibility control tortuous arterial anatomy . Each individual stent graft device supply sterile pre-loaded single-use delivery system . The stent graft self-expanding endoprosthesis construct thin wall woven polyester nitinol ring stent , attach fabric braid polyester suture . The delivery system central catheter stainless steel braid co-extrusion polytetrafluoroethylene ( PTFE ) polyester elastomer , design provide significant torque control strength , also maintain superior flexibility . The outer sheath make tri-layer construction consist PTFE liner , stainless steel flat braid layer polyester elastomer outer jacket hydrophilic lubricant coating . These material provide low friction force device insertion deployment together enhance flexibility delivery system . The handle component mould thermoplastic polyurethane . The material endoprosthesis identical current Conformité Européenne ( CE ) mark Vascutek Ltd. AnacondaTM Stent Graft System intend abdominal aortic aneurysm repair . The material delivery system well establish medical application . The design ThoraflexTM base principle clinically establish thoracic endovascular device . The endoprosthesis construct self-expanding nitinol stent polyester tube graft . Four proximal hook anchor endoprosthesis within aorta . Unlike exist thoracic endovascular device , delivery system ThoraflexTM allow reposition endoprosthesis optimal deployment position enhance . The intend use ThoraflexTM treatment aneurysm penetrate ulcer descend thoracic aorta , identical CE approve thoracic endovascular device .</brief_summary>
	<brief_title>Evaluation Thoraflex Treatment Aneurysm Penetrating Ulcer Descending Thoracic Aorta</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Thoracic</mesh_term>
	<criteria>1 . Subject age &gt; 18 year 2 . Subject life expectancy least 12 month 3 . The Subject must meet least one following : 1 . Descending thoracic fusiform aneurysm , 50mm diameter great . ONLY FOR FRENCH SITES : Descending thoracic fusiform aneurysm , 5.5cm diameter great . 2 . Descending thoracic aneurysm 4cm diameter increase size 0.5cm last 6 month . ONLY FOR FRENCH SITES : Descending thoracic aneurysm 4cm diameter increase size 1cm last year 3 . Descending thoracic aneurysm maximum diameter exceed two time diameter nonaneurysmal , adjacent aorta 4 . Saccular aneurysm descend thoracic aorta Penetrating Atherosclerotic Ulcers ( PAUs ) . ONLY FOR FRENCH SITES : Saccular aneurysm descend thoracic aorta , Penetrating Atherosclerotic Ulcers ( PAUs ) associate Intramural Haematoma , Atherosclerotic Giant PAU 4 . Subject must proximal distal aortic neck suitable stent graft placement vessel diameter range 22.0 35.0 mm . 5 . The length attachment zone depend intend stent graft diameter . For left subclavian artery ( LSA ) superior position : The proximal attachment zone 10mm 28mm graft , 11mm 30mm , 12mm 32mm 34mm graft , 14mm 36mm 38mm graft 15mm 40mm graft . For LSA nonsuperior position : The proximal attachment zone 15mm 28mm graft , 17mm 30mm , 20mm 32mm 34mm graft , 23mm 36mm 38mm graft 25mm 40mm graft . The distal attachment zone 40mm . 6 . The diagnosis confirm thoracic aortic aneurysm PAU contrast enhance CT obtain within three month prior implant . 7 . Access vessel : Adequate iliac/femoral access able accommodate 23 ( 7.7 mm ) 25 OD French size ( 8.3 mm ) introducer system , without use arterial conduit . 8 . Subject able willing comply protocol associate followup requirement 9 . Subject legal representative must agree participate voluntarily sign date Ethics Committee/Ethical Review Board approve Patient Informed Consent form . 1 . Subject follow condition his/her descend thoracic aorta : 1 . Dissections acute chronic , ascend descend aorta 2 . Acute Transection Acute Traumatic Injury 3 . Pseudoaneurysm ( false aneurysm ) 4 . Symptomatic Aneurysm , include ruptured lesion 2 . Subject 's proximal neck diameter measure &lt; 22.0 &gt; 35.0 mm . 3 . Subject 's distal neck diameter measure &lt; 22.0 &gt; 35.0 mm . 4 . Subject prohibitive calcification ( &gt; 50 % circumferential calcification ) , occlusive disease , tortuosity intend fixation site . 5 . Subject circumferential thrombus ( &gt; 50 % ) region intend fixation site . 6 . Subject increase tapered proximal neck ≥3mm increase diameter proximal fixation site aneurysm . 7 . Subject decreasing taper distal neck ≥3 mm increase diameter distal fixation site aneurysm . 8 . Subject 's aneurysm distal thoracic aortic neck angle precludes advancement introduction system device . 9 . Subject anatomical variance would compromise circulation carotids , vertebral , innominate artery device placement amenable subclavian revascularisation . This would apply Subjects occluded celiac artery . 10 . Subject pregnant . 11 . Subject morbidly obese prevent adequate xray visualization aorta . 12 . Subject know suspected connective tissue disorder ( e.g. , Marfan 's syndrome , EhlersDanlos syndrome ) . 13 . Subject blood coagulation disorder bleed diathesis treatment suspend one week pre post repair . 14 . Subject coronary artery disease unstable angina receive coronary revascularisation within last 3 month . 15 . Subject chronic obstructive pulmonary disease require routine need oxygen therapy outside hospital setting ( e.g. , daily nightly home use ) . 16 . Subject acute renal failure renal insufficiency creatinine ≥ 2.5 mg/dL renal replacement therapy dialysis . 17 . Subject active systemic infection and/or mycotic aneurysm . 18 . Subject stroke within 3 month treatment date . 19 . Subject less oneyear life expectancy evidence factor prohibit major medical intervention ( e.g. , presence malignant tumour , advanced age , etc. ) . 20 . Subject participate another research study . 21 . Subject coexist abdominal aortic aneurysm ( AAA ) investigator believe require concomitant treatment within 45 day . 22 . Subject prior AAA repair ( endovascular surgical ) perform less 6 month prior enrolment . 23 . Subject prior endovascular repair ( e.g. , stent , stentgraft ) descend thoracic aorta . The device may place within prior surgical graft . 24 . Subject untreatable allergy sensitivity contrast medium device component . 25 . Subject admit hospital major surgical medical procedure within45 day plan procedure planning undergo major surgical medical procedure within 45 day post implantation ( e.g. , coronary artery bypass graft [ CABG ] , organ transplantation , etc. ) . This exclude planned procedure prospective stentgraft placement ( e.g . common carotid leave subclavian transposition/bypass , leave carotid axillary bypass , etc . acceptable . Carotidcarotid bypass permit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>aneurysm , penetrate ulcer , descend thoracic aorta</keyword>
</DOC>